|
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection |
No comment yet.
Sign up to comment
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Immunology
173.7K views |
+16 today
Teaching and Learning Immunology. Information you never would have searched for!
Curated by
Gilbert C FAURE
 Your new post is loading...
Your new post is loading...
|
Scoop.it!
Lung cancer uses cunning mechanisms to evade the immune system. Can new antibody therapies outwit the disease? Via Krishan Maggon
Krishan Maggon 's curator insight,
September 11, 2014 12:03 PM
After 20 years of treating lung cancer, and 20 years of dashed hopes in lung-cancer immunotherapy, there is finally a glimmer of hope in both vaccines and non-vaccine immunotherapies, such as the PD-1 and PD-L1 inhibitors.
If the past decades of failure have taught the industry anything, it is that early trial success rarely leads to a breakthrough drug. Phase III trial data from the checkpoint inhibitors and the vaccines are eagerly awaited. Open access NATURE | OUTLOOK Immunotherapy: Chemical tricksBianca NogradyNature 513, S10–S11 (11 September 2014) doi:10.1038/513S10aPublished online 10 September 2014 |
The emergence of immuno-oncology, in which a patient’s own immune system is activated to fight the cancer, has shown promise in certain tumor subtypes, notably with therapies such as ipilimumab, which has been approved for metastatic melanoma.
But immuno-oncology presents certain challenges. Patients may not be “cured” in the conventional sense; rather, the disease may be converted to a chronic condition. In some cases the person can return to work, but in others, that’s not possible. This raises important policy choices when employers pay for healthcare. - See more at: http://www.ajmc.com/publications/evidence-based-oncology/2014/November-2014/AJMC-Panel-Explores-Immuno-oncology-and-What-Making-Cancer-a-Chronic-Condition-Means-for-Payers#sthash.Cr9sqCWa.dpuf